Literature DB >> 10559634

Flow cytometric immunodissection of the human nephron in vivo and in vitro.

M J Helbert1, S Dauwe, M E De Broe.   

Abstract

In the present article, we show that flow cytometric immunodissection of cells immediately following their preparation from a tumor nephrectomy specimen is an accurate way of obtaining pure human primary cultures of proximal convoluted tubule origin, proximal straight tubule origin, distal tubular origin and/or collecting duct origin. By studying the expression of a panel of cell surface markers in these purified cultures, we could identify a number of markers that retain their lineage specificity in vitro. Using these appropriate stable markers, flow cytometry provides a simple yet accurate way of determining cell composition in previously unsorted (mixed type) tubular epithelial cultures in terms of proximal versus distal tubule/collecting duct subpopulations. Both subpopulations in mixed type cultures are shown to retain functional characteristics of their in vivo counterparts (glucose uptake, hormonal stimulation of adenylate cyclase) as well as cell type-specific response patterns (such as inducibility of cell adhesion and histocompatibility molecules), indicating the usefulness of studying cell responses in vitro in a cell-type-dependent way. Finally we illustrate that multi-parameter flow cytometry is a powerful tool for assessing constitutive characteristics of and/or responses by the distinct cell subpopulations present in mixed type cultures. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559634     DOI: 10.1159/000020634

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  2 in total

1.  Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.

Authors:  Anja Verhulst; Shuting Sun; Charles E McKenna; Patrick C D'Haese
Journal:  PLoS One       Date:  2015-03-10       Impact factor: 3.240

Review 2.  Cell-based therapy for kidney disease.

Authors:  Hyun Chul Chung; In Kap Ko; Anthony Atala; James J Yoo
Journal:  Korean J Urol       Date:  2015-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.